Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irene Mittermann has a total of 625 co-authors. Here are the top co-authors by number of shared publications:

  • Rudolf Valenta

    Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria; NRC Institute of Immunology FMBA of Russia, Moscow, Russia; Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia; Karl Landsteiner University of Health Sciences, Krems, Austria

    21 shared publications
  • Rudolf Valenta

    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria

    16 shared publications
  • Christian Lupinek

    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria

    9 shared publications
  • Susanne Vrtala

    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria

    7 shared publications
  • Pia Gattinger

    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria

    6 shared publications
  • Annice Heratizadeh

    Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany

    5 shared publications

Latest Publications

  • Open Access

    A proposed thaumatin-like protein (TLP) syndrome: Sensitization patterns, reaction severity, and multiple-fruit reactivity in Thai and Austrian banana-allergic adult cohorts

    by Mongkhon Sompornrattanaphan, Stefan Kabasser, Wolfgang Hemmer, Daniel Bernklau, Emira Sheshori, Martina Aumayr, Irene Mittermann, Thanachit Krikeerati, Irin Vichara-Anont, Piyaporn Chokevittaya, et al.

  • Open Access

    Lettuce Anaphylaxis in a Florist With Hand Dermatitis and Contact Allergy to the Compositae ( Asteraceae ) Family of Plants

    by Lara Obermeyer, Monika Raulf, Irene Mittermann, Martina Aumayr, Christoph Skudlik, Richard Brans


  • Open Access

    Big Data-Driven Evolution of a Diagnostic Multiplex IgE-Test: Enhancing Accuracy and Efficacy in Allergy Diagnostics

    by Christian Lupinek, Peter Forstenlechner, Anna Ringauf, Raffaela Campana, Artan Salihu, Martina Aumayr, Irene Mittermann

    The ALEX2-test (MacroArray Diagnostics, Vienna, Austria) is a diagnostic multiplex IgE-test for the simultaneous detection of IgE to 178 allergens and 117 extracts, in addition to total IgE. Test results from more than 90 countries are stored on a GDPR-compliant cloud server for backup, customer support, and continuous postmarket surveillance. To improve the coverage of exposomes on a global scale and to further increase the sensitivity of the test, the allergen panel was updated from ALEX2 to ALEX3. By mid-2023, when ALEX3 was designed, almost 400,000 real-world ALEX2 test results were available. Analysing prevalences and average sIgE-levels of individual allergen preparations, coverage of extracts by components, and co-reactivity of members of the same allergen family provided a rationale for updating the array. In parallel, based on the scientific literature and clinical studies, new allergens were selected. On ALEX3, 218 allergens and 82 extracts will be represented, including 52 new allergens. Allergen preparations with low prevalence and clinical relevance, as well as redundant allergens and extracts, were discontinued. New allergens encompass, e.g., cyclophilins, alpha-gal, and additional markers from respiratory and food allergen sources. Using a large dataset of ALEX2 test results exemplifies the targeted, data-driven improvement of a diagnostic IgE-macroarray.


  • Response to Gattinger et al

    by Christian Lupinek, Irene Mittermann, Peter Forstenlechner, Sandra Wieser

  • Open Access

    Glycosylation enhances allergenic activity of major bee venom allergen Api m 1 by adding IgE epitopes

    by Pia Gattinger, Urska Bidovec-Stojkovic, Mihaela Zidarn, Peter Korosec, Rudolf Valenta, Irene Mittermann


  • Molecular IgE sensitization profiles of urban and rural children in South Africa

    by Irene Mittermann, Sheron Dzoro, Pia Gattinger, Maresa Botha, Wisdom Basera, Heidi E Facey-Thomas, Ben Gaunt, Jon Genuneit, Claudia L Gray, Carol Hlela, et al.

    Background: Allergens can act as disease‐triggering factors in atopic dermatitis (AD) patients. The aim of the study was to elucidate the molecular IgE sensitization profile in children with and without AD living in urban and rural areas of South Africa.Methods: Specific IgE reactivity was assessed in 166 Black South African children aged 9‐38 months using a comprehensive panel of microarrayed allergens. According to clinical characterization children fell in four groups, urban AD cases (n = 32), urban controls (non‐AD, n = 40), rural cases (n = 49) and rural controls (non‐AD, n = 45).Results: IgE reactivity to at least one of the allergens was detected in 94% of urban and 86% of rural AD children. House dust mite (HDM; 81% urban, 74% rural AD) and animal‐derived allergens (50% urban, 31% rural AD) were the most frequently recognized respiratory allergens, whereas IgE to pollen allergens was almost absent. Urban AD children showed significantly higher frequency of IgE reactivity (50%) to mouse lipocalin, Mus m 1, than rural AD children (12%). The most frequently recognized food allergens were from egg (63% urban, 43% rural AD), peanut (31% vs 41%), and soybean (22% vs 27%), whereas milk sensitization was rare. α‐gal‐specific IgE almost exclusively occurred in rural children (AD: 14%, non‐AD: 49%).Conclusion: Molecular allergy diagnosis detects frequent IgE sensitization to HDM, animal but not pollen allergens and to egg, peanut, and soy, but not milk allergens in African AD children. Urban AD children reacted more often to Mus m 1, whereas α‐gal sensitization is more common in rural children likely due to parasite exposure.


  • Fluorescent labeling of major honeybee allergens Api m 1 and Api m 2 with quantum dots and the development of a multiplex basophil activation test

    by Ana Koren, Mojca Lunder, Peter Molek, Peter Kopač, Abida Zahirović, Pia Gattinger, Irene Mittermann, Rudolf Valenta, Peter Korošec


  • Open Access

    Recombinant glycoproteins resembling carbohydrate-specific IgE epitopes from plants, venoms and mites

    by Pia Gattinger, Irene Mittermann, Christian Lupinek, Gerhard Hofer, Walter Keller, Urska Bidovec Stojkovic, Peter Korosec, Christine Koessler, Natalija Novak, Rudolf Valenta


  • Open Access

    Prevention of allergy by virus‐like nanoparticles (VNP) delivering shielded versions of major allergens in a humanized murine allergy model

    by Bernhard Kratzer, Cordula Köhler, Sandra Hofer, Ursula Smole, Doris Trapin, Jagoba Iturri, Dietmar Pum, Philip Kienzl, Adelheid Elbe‐Bürger, Pia Gattinger, et al.

    Background: In high‐risk populations, allergen‐specific prophylaxis could protect from sensitization and subsequent development of allergic disease. However, such treatment might itself induce sensitization and allergies, thus requiring hypoallergenic vaccine formulations. We here characterized the preventive potential of virus‐like nanoparticles (VNP) expressing surface‐exposed or shielded allergens.Methods: Full‐length major mugwort pollen allergen Art v 1 was selectively targeted either to the surface or to the inner side of the lipid bilayer envelope of VNP. Upon biochemical and immunological analysis, their preventive potential was determined in a humanized mouse model of mugwort pollen allergy.Results: Virus‐like nanoparticles expressing shielded version of Art v 1, in contrast to those expressing surface‐exposed Art v 1, were hypoallergenic as they hardly induced degranulation of rat basophil leukemia cells sensitized with Art v 1‐specific mouse or human IgE. Both VNP versions induced proliferation and cytokine production of allergen‐specific T cells in vitro. Upon intranasal application in mice, VNP expressing surface‐exposed but not shielded allergen induced allergen‐specific antibodies, including IgE. Notably, preventive treatment with VNP expressing shielded allergen‐protected mice from subsequent sensitization with mugwort pollen extract. Protection was associated with a Th1/Treg‐dominated cytokine response, increased Foxp3+ Treg numbers in lungs, and reduced lung resistance when compared to mice treated with empty particles.Conclusion: Virus‐like nanoparticles represent a novel and versatile platform for the in vivo delivery of allergens to selectively target T cells and prevent allergies without inducing allergic reactions or allergic sensitization.


  • Open Access

    The culprit insect but not severity of allergic reactions to bee and wasp venom can be determined by molecular diagnosis

    by Pia Gattinger, Christian Lupinek, Lampros Kalogiros, Mira Silar, Mihaela Zidarn, Peter Korosec, Christine Koessler, Natalija Novak, Rudolf Valenta, Irene Mittermann

    Allergy to bee and wasp venom can lead to life-threatening systemic reactions. The identification of the culprit species is important for allergen-specific immunotherapy. To determine a panel of recombinant bee and wasp allergens which is suitable for the identification of bee or wasp as culprit allergen sources and to search for molecular surrogates of clinical severity of sting reactions. Sera from eighty-seven patients with a detailed documentation of their severity of sting reaction (Mueller grade) and who had been subjected to titrated skin testing with bee and wasp venom were analyzed for bee and wasp-specific IgE levels by ImmunoCAPTM. IgE-reactivity testing was performed using a comprehensive panel of recombinant bee and wasp venom allergens (rApi m 1, 2, 3, 4, 5 and 10; rVes v 1 and 5) by ISAC chip technology, ImmunoCAP and ELISA. IgG4 antibodies to rApi m 1 and rVes v 5 were determined by ELISA and IgE/IgG4 ratios were calculated. Results from skin testing, IgE serology and IgE/IgG4 ratios were compared with severity of sting reactions. The panel of rApi m 1, rApi m 10, rVes v 1 and rVes v 5 allowed identification of the culprit venom in all but two of the 87 patients with good agreement to skin testing. Severities of sting reactions were not associated with results obtained by skin testing, venom-specific IgE levels or molecular diagnosis. Severe sting reactions were observed in patients showing < 1 ISU and < 2kUA/L of IgE to Api m 1 and/or Ves v 5. We identified a minimal panel of recombinant bee and wasp allergens for molecular diagnosis which may permit identification of bee and/or wasp as culprit insect in venom-sensitized subjects. The severity of sting reactions was not associated with parameters obtained by molecular diagnosis.